Real-world Digital Biomarkers Associated With Their Clinical Counterparts in the MS-DETECT Study (P4-18.004)

Patrick Vermersch; Massimo Filippi; Celia Oreja‐Guevara; Jiwon Oh; Tobias Sejbæk; Jennifer Graves; Lissandra Klaeylé; Séverine Bieuvelet; Loïc Carment; Pierre DROUIN; Saad Zinaï; Pascal Rufi; Bruno Padrazzi; Tjalf Ziemssen

doi:10.1212/wnl.0000000000216110

June 9, 2026Neurology

Real-world Digital Biomarkers Associated With Their Clinical Counterparts in the MS-DETECT Study (P4-18.004)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to compare digital biomarkers obtained through MSCopilot with clinical assessments from MSCF-4 scores at the baseline.
Interim analysis from the MS-DETECT study
Comparison of MSCopilot® digital biomarkers measured in-clinic or at-home with MSCF-4 scores
Baseline data collection and analysis.
Initial findings show differences between digital biomarkers and clinical scores.
Further understanding of how digital measurements correlate with traditional assessments.

Implication

Interim analysis compares digital biomarkers with clinical scores in individuals, suggesting potential clinical relevance.

Abstract

This interim analysis describes baseline comparisons between MSCopilot® digital biomarkers, measured in-clinic or at-home, and individual MSCF-4 scores.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vermersch et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0561e6 https://doi.org/10.1212/wnl.0000000000216110

View Full Paper

Ask AI

Bookmark

Share

Real-world Digital Biomarkers Associated With Their Clinical Counterparts in the MS-DETECT Study (P4-18.004)

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world Digital Biomarkers Associated With Their Clinical Counterparts in the MS-DETECT Study (P4-18.004)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading